NCOR2 inhibits anti-tumor therapy by modulating HDAC3 to suppress gene expression dependent on IRF-1 and the IFN signaling pathway. Altering the interaction between NCOR2 and HDAC3, reducing NCOR2, or impeding its epigenetic activity enhances chemotherapy responsiveness and restores anti-tumor immunity. This evidence concerns the gene IRF1 and neoplasm.